231 related articles for article (PubMed ID: 31281074)
1. Intra arterial treatment of hepatocellular carcinoma: Comparison of MELD score variations between radio-embolization and chemo-embolization.
Delicque J; Hermida M; Piron L; Allimant C; Belgour A; Pageaux GP; Ben Bouallegue F; Assenat E; Mariano-Goulart D; Guiu B; Cassinotto C
Diagn Interv Imaging; 2019 Nov; 100(11):689-697. PubMed ID: 31281074
[TBL] [Abstract][Full Text] [Related]
2. Validation and prognostic value of EZ-ALBI score in patients with intermediate-stage hepatocellular carcinoma treated with trans-arterial chemoembolization.
Ananchuensook P; Sriphoosanaphan S; Suksawatamnauy S; Siripon N; Pinjaroen N; Geratikornsupuk N; Kerr SJ; Thanapirom K; Komolmit P
BMC Gastroenterol; 2022 Jun; 22(1):295. PubMed ID: 35701739
[TBL] [Abstract][Full Text] [Related]
3. Comparison of MELD and Child-Pugh scores to predict survival after chemoembolization for hepatocellular carcinoma.
Brown DB; Fundakowski CE; Lisker-Melman M; Crippin JS; Pilgram TK; Chapman W; Darcy MD
J Vasc Interv Radiol; 2004 Nov; 15(11):1209-18. PubMed ID: 15525739
[TBL] [Abstract][Full Text] [Related]
4. Outcome and prognostic factors of spontaneous ruptured hepatocellular carcinoma treated with transarterial embolization.
Shin BS; Park MH; Jeon GS
Acta Radiol; 2011 Apr; 52(3):331-5. PubMed ID: 21498371
[TBL] [Abstract][Full Text] [Related]
5. ALBI and P-ALBI grade in Child-Pugh A patients treated with drug eluting embolic chemoembolization for hepatocellular carcinoma.
Carling U; Røsok B; Line PD; Dorenberg EJ
Acta Radiol; 2019 Jun; 60(6):702-709. PubMed ID: 30205701
[TBL] [Abstract][Full Text] [Related]
6. Boosted-Dose Yttrium-90 Radiation Segmentectomy or Lobectomy for Hepatocellular Carcinoma Refractory to Prior Transarterial Embolization or Chemoembolization: A Single Institution Retrospective Case Series.
Srinivas S; Rose SC; Al Jammal O; Hsieh LJ; Rockwell HD; Duncan DP; Minocha J; Berman ZT
Cardiovasc Intervent Radiol; 2023 Apr; 46(4):460-469. PubMed ID: 36854903
[TBL] [Abstract][Full Text] [Related]
7. Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma.
Kolligs FT; Bilbao JI; Jakobs T; Iñarrairaegui M; Nagel JM; Rodriguez M; Haug A; D'Avola D; op den Winkel M; Martinez-Cuesta A; Trumm C; Benito A; Tatsch K; Zech CJ; Hoffmann RT; Sangro B
Liver Int; 2015 Jun; 35(6):1715-21. PubMed ID: 25443863
[TBL] [Abstract][Full Text] [Related]
8. Randomized comparison of selective internal radiotherapy (SIRT) versus drug-eluting bead transarterial chemoembolization (DEB-TACE) for the treatment of hepatocellular carcinoma.
Pitton MB; Kloeckner R; Ruckes C; Wirth GM; Eichhorn W; Wörns MA; Weinmann A; Schreckenberger M; Galle PR; Otto G; Dueber C
Cardiovasc Intervent Radiol; 2015 Apr; 38(2):352-60. PubMed ID: 25373796
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma.
Golfieri R; Bilbao JI; Carpanese L; Cianni R; Gasparini D; Ezziddin S; Paprottka PM; Fiore F; Cappelli A; Rodriguez M; Ettorre GM; Saltarelli A; Geatti O; Ahmadzadehfar H; Haug AR; Izzo F; Giampalma E; Sangro B; Pizzi G; Notarianni E; Vit A; Wilhelm K; Jakobs TF; Lastoria S;
J Hepatol; 2013 Oct; 59(4):753-61. PubMed ID: 23707371
[TBL] [Abstract][Full Text] [Related]
10. Trans-arterial chemoembolization with degradable starch microspheres (DSM-TACE) versus selective internal radiation therapy (SIRT) in multifocal hepatocellular carcinoma.
Auer TA; Jonczyk M; Collettini F; Marth A; Wieners G; Hamm B; Gebauer B
Acta Radiol; 2021 Mar; 62(3):313-321. PubMed ID: 32498543
[TBL] [Abstract][Full Text] [Related]
11. SIRT Compared with DEB-TACE for Hepatocellular Carcinoma: a Real-world Study (the SITAR Study).
Hirsch RD; Mills C; Sawhney R; Sood S; Bird V; Mishra G; Dev A; Kemp W; Lubel J; Roberts SK; Gow P; Nicoll AJ
J Gastrointest Cancer; 2021 Sep; 52(3):907-914. PubMed ID: 32901445
[TBL] [Abstract][Full Text] [Related]
12. Retrospective analysis of the immunogenic effects of intra-arterial locoregional therapies in hepatocellular carcinoma: a rationale for combining selective internal radiation therapy (SIRT) and immunotherapy.
Craciun L; de Wind R; Demetter P; Lucidi V; Bohlok A; Michiels S; Bouazza F; Vouche M; Tancredi I; Verset G; Garaud S; Naveaux C; Galdon MG; Gallo KW; Hendlisz A; Derijckere ID; Flamen P; Larsimont D; Donckier V
BMC Cancer; 2020 Feb; 20(1):135. PubMed ID: 32075608
[TBL] [Abstract][Full Text] [Related]
13. A differential risk assessment and decision model for Transarterial chemoembolization in hepatocellular carcinoma based on hepatic function.
Nam JY; Choe AR; Sinn DH; Lee JH; Kim HY; Yu SJ; Kim YJ; Yoon JH; Lee JM; Chung JW; Choi SY; Lee JK; Baek SY; Lee HA; Kim TH; Yoo K
BMC Cancer; 2020 Jun; 20(1):504. PubMed ID: 32487089
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of transcatheter embolization/chemoembolization (TAE/TACE) for the treatment of single hepatocellular carcinoma.
Miraglia R; Pietrosi G; Maruzzelli L; Petridis I; Caruso S; Marrone G; Mamone G; Vizzini G; Luca A; Gridelli B
World J Gastroenterol; 2007 Jun; 13(21):2952-5. PubMed ID: 17589945
[TBL] [Abstract][Full Text] [Related]
15. Conventional transarterial chemoembolization vs microsphere embolization in hepatocellular carcinoma: a meta-analysis.
Ni JY; Xu LF; Wang WD; Sun HL; Chen YT
World J Gastroenterol; 2014 Dec; 20(45):17206-17. PubMed ID: 25493037
[TBL] [Abstract][Full Text] [Related]
16. ASARA, a prediction model based on Child-Pugh class in hepatocellular carcinoma patients undergoing transarterial chemoembolization.
Jia KF; Wang H; Yu CL; Yin WL; Zhang XD; Wang F; Sun C; Shen W
Hepatobiliary Pancreat Dis Int; 2023 Oct; 22(5):490-497. PubMed ID: 35260337
[TBL] [Abstract][Full Text] [Related]
17. Morbidity and mortality following transarterial liver chemoembolization in patients with hepatocellular carcinoma and synthetic hepatic dysfunction.
Garwood ER; Fidelman N; Hoch SE; Kerlan RK; Yao FY
Liver Transpl; 2013 Feb; 19(2):164-73. PubMed ID: 23008091
[TBL] [Abstract][Full Text] [Related]
18. Value of the model for end-stage liver disease for predicting survival in hepatocellular carcinoma patients treated with transarterial chemoembolization.
Kim JH; Kim JH; Choi JH; Kim CH; Jung YK; Yim HJ; Yeon JE; Park JJ; Kim JS; Bak YT; Byun KS
Scand J Gastroenterol; 2009; 44(3):346-57. PubMed ID: 18991165
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of Initial Transarterial Chemoembolization for Hepatocellular Carcinoma Among Medicare Beneficiaries.
Sanoff HK; Chang Y; Stavas JM; Stürmer T; Lund J
J Natl Compr Canc Netw; 2015 Sep; 13(9):1102-10. PubMed ID: 26358794
[TBL] [Abstract][Full Text] [Related]
20. Hepatic Function during Repeated TACE Procedures and Prognosis after Introducing Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: Multicenter Analysis.
Hiraoka A; Kumada T; Kudo M; Hirooka M; Koizumi Y; Hiasa Y; Tajiri K; Toyoda H; Tada T; Ochi H; Joko K; Shimada N; Deguchi A; Ishikawa T; Imai M; Tsuji K; Michitaka K;
Dig Dis; 2017; 35(6):602-610. PubMed ID: 29040999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]